Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) – Stock analysts at SVB Leerink upped their FY2024 earnings per share (EPS) estimates for shares of Reata Pharmaceuticals in a research report issued to clients and investors on Monday, June 12th. SVB Leerink analyst J. Schwartz now forecasts that the company will post earnings per share of […]
Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) CAO Bhaskar Anand sold 2,343 shares of the company’s stock in a transaction dated Wednesday, June 14th. The shares were sold at an average price of $102.11, for a total transaction of $239,243.73. Following the sale, the chief accounting officer now directly owns 24,898 shares of the company’s […]
Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) CAO Bhaskar Anand sold 2,343 shares of Reata Pharmaceuticals stock in a transaction on Wednesday, June 14th. The shares were sold at an average price of $102.11, for a total value of $239,243.73. Following the completion of the sale, the chief accounting officer now owns 24,898 shares in […]
Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) has received an average recommendation of “Moderate Buy” from the eleven ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on the company. The […]
SVB Leerink upgraded shares of Reata Pharmaceuticals (NASDAQ:RETA – Get Rating) from a market perform rating to an outperform rating in a report issued on Monday, PriceTargets.com reports. SVB Leerink also issued estimates for Reata Pharmaceuticals’ FY2024 earnings at ($5.41) EPS. Other equities analysts also recently issued research reports about the company. Citigroup boosted their […]